Adocia Sa · EURONEXT:ADOC
Adocia Sa — Investor Presentation (January 2024)
23 slides from Adocia Sa's investor presentation, January 2024
Slide 1: Innovative BioTherapies From Diabetes to Obesity
Innovative BioTherapies From Diabetes to Obesity January 2024 (ADOC)
Slide 2: Forward-looking statements
Forward-looking statements This corporate presentation (the “Presentation”) has been prepared by ADOCIA S.A. (the “Company” and, together with its subsidiary, the “Group”) and is provided for information purposes only. It is not for promotional use. References herein to the Presentation shall mean a
Slide 3: Adocia: focused on innovation, turned towards partnerships
Adocia: focused on innovation, turned towards partnerships 1 Mission: Revolutionizing treatment of insulin-dependent people suffering from obesity, and curing type 1 diabetes by cell therapy without immunosuppression 2 Focus: Development of innovative formulations of approved peptides and novel deli
Slide 4: Experienced team in delivering innovative hormonal treatments
Experienced team in delivering innovative hormonal treatments Gérard Soula Olivier Soula Valérie PhD, MBA PhD, MBA Danaguezian President CEO Chief Financial Officer Co-founder Co-founder 2005 2012 80 people w. €95m funds Founded by the raised 25 patent IPO 35 families Soula family $135m from ADOC Ph
Slide 5: Adocia, a pure play innovator dedicated to diabetes and obesity patients
Adocia, a pure play innovator dedicated to diabetes and obesity patients BC Lispro & BC Combo Founded on BioChaperone® platform’ successes Securing revenues (up to $80m + DIABETES & OBESITY Asia & other territories royalties) M1Pram Reduces weight & maintains glycemic control Exclusive negotiation r
Slide 6: Balanced pipeline with highly innovative products from preclinical to Ph.3
Balanced pipeline with highly innovative products from preclinical to Ph.3, demonstrating ability to bring project at industrial level Preclinic Phase 1 Phase 2 Phase 3 Status / Upcoming milestones Partner Diabetes Asia & other Ph 3 in China: Recruitment almost completed territories BC Lispro Ultra-
Slide 7: BC Lispro and BC Combo partnered with Chinese Leader Tonghua Dongbao (THDB)
BC Lispro and BC Combo partnered with Chinese Leader Tonghua Dongbao (THDB) 78% $3bn 200 million people with of revenue diabetes in Market from covered Cap2 insulin1 territories3 1. Data THDB 2. June 2022 3. Asia and other territories 7 7
Slide 8: THDB licenses for China should ensure steady revenue over next years
THDB licenses for China should ensure steady revenue over next years BioChaperone Lispro BioChaperone Combo Faster profile for less hyper- and less hypoglycemia 2-in-1 Product ensuring both basal & prandial control Deal Deal • $15m (upfront + milestone received) • $40m upfront • $30m milestones to c
Slide 9: M1Pram Insulin & amylin analogs combination
M1Pram Insulin & amylin analogs combination Breakthrough treatment to address the unmet medical need of obesity in insulin-dependent people 9 9
Slide 10: The satiety hormones revolution
The satiety hormones revolution GLP1-RA AMYLIN Secreted by intestine Secreted by pancreatic β cells Brain, Stomach Appetite, Food intake, Gastric emptying, Energy expenditure Stimulate β cells to secrete Pancreas Directly replaces missing amylin insulin/amylin Weight loss, Glycemic control,
Slide 11: In the U.S., 2 million insulin-dependent people suffer from obesity
In the U.S., 2 million insulin-dependent people (incl. T1D and T2D) suffer from obesity They rely on insulin for survival … whereas insulin, a growth hormone, promotes weight gain 1m T1D (65%) overweight/ • T1D: GLP-1 are not approved obese 2 million • T2D: GLP-1 approved people under IIT* … neverth
Slide 12: M1Pram simply replaces usual mealtime insulin
M1Pram simply replaces usual mealtime insulin Gold Standard Mealtime Insulin M1Pram = Insulin + Amylin ✓ Same number and time of injections as standard mealtime insulin ✓ Same glycemic control maintained ✓ Same risk of hypoglycemia ✓ Same local tolerance Weight loss Weight gain ✓ Equivalent weight l
Slide 13: M1Pram has demonstrated exceptional weight loss in obese T1D
M1Pram has demonstrated exceptional weight loss in obese T1D CT041 : Phase 2 study – M1Pram vs. lispro (Humalog®) - type 1 diabetes GLP-1 are not approved in T1D → Associated with risk of ketosis and hypo/hyperglycemia1 Insulin lispro (Humalog®) -0.57 kg (-0.74%), N=9 Closest comparator: GLP-1 + bas
Slide 14: M1Pram: potential first-line treatment for people with obesity under intensive insulin therapy
M1Pram: potential first-line treatment for people with obesity under intensive insulin therapy Large & Growing Price parity Unmet Chronic & patient with GLP-1 Blockbuster Medical Vital reservoir potential Need treatment $12,000 2 million /year (U.S.) (U.S.) No competitive product has been identified
Slide 15: M1Pram development plan & key value inflexion points
M1Pram development plan & key value inflexion points Sanofi has acquired for €10m a time-limited exclusive right to negotiate a worldwide licensing transaction Ph. 2b results in T1D and Ph. 3 readiness Phase 2 Proof-of-Concept Next development steps Exceptional weight loss in T1D while - Clinical ba
Slide 16: AdoShell Islets
AdoShell® Islets Immunoprotective scaffold for islets transplantation as a potential cure for type 1 diabetes 16 16
Slide 17: AdoShell Islets: the promise of cell therapy without immunosuppression
AdoShell® Islets: the promise of cell therapy without immunosuppression Islet transplantation has regulatory approvals Clinical application is restricted due to AEs of immunosuppressants, used to avoid rejection AdoShell Islets: designed to overcome the important challenges in diabetes cell therapy
Slide 18: AdoShell: immunoprotective hydrogel for cell therapy
AdoShell®: immunoprotective hydrogel for cell therapy Biocompatible polymers Immuno-isolation Ab, T cells Large entities > 10 nm + + Laparoscopy AdoShell® Islets Free diffusion Oxygen, Glucose, Insulin Small entities < 5 nm Insulin-secreting 132-day study in diabetic cells immunocompetent rats Pancr
Slide 19: AdoShell Islet development plan & key value inflection points
AdoShell® Islet development plan & key value inflection points Partnering IP generation Preclinical POC Adocia files a patent on a hydrogel scaffold with human islets for cell therapy in the treatment of T1D in diabetic mice 2021 2022 2023 2024 First-in-Human Efficacy evidence in animal Oral present
Slide 20: Financials & Conclusions
Financials & Conclusions 20 20
Slide 21: Key financials
Key financials • Financial position - end of September: Shareholder ownership Nov. 30, 2023 • Cash position: €16.8m • Indebtedness: €5.6 m (PGE debt maturing Aug. 2026) • No convertible nor warrant pending Soula Family Free float & Employees 67,9% Pool 14,5% • Listed on Euronext Paris (ADOC): • 14 m
Slide 22: 2024/2025: Major transformative value inflexion points
2024/2025: Major transformative value inflexion points 2024 2025 BC Lispro/BC Combo Solid partnership with 1 In China: Tonghua Dongbao BC Lispro: marketing BC Lispro: completion of Ph. 3 authorization in China BC Combo: initiation of Ph. 3 M1Pram 2 Major partnership Licensing transaction w. Sanofi L
Slide 23: Thank you for your interest
Thank you for your interest 115 avenue Lacassagne 69003 Lyon – FRANCE Ph.:+33 4 72 610 610 contactinvestisseurs@adocia.com (ADOC)